Journal
JOURNAL OF CORPORATE FINANCE
Volume 84, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jcorpfin.2023.102495
Keywords
FDA; Informed trading; Options
Categories
Ask authors/readers for more resources
There is significant abnormal options trading before FDA drug approvals, particularly for small drug firms. These trades seem to be informed, as there are more calls (puts) purchased before approvals (rejections), and a majority have maturities covering the dates when the reports are publicly released. Therefore, securities regulators should consider monitoring these trades early.
Months before the Food and Drug Administration (FDA) decides to approve or reject a new drug, it often asks committees of drug experts for their recommendations. The experts receive nonpublic technical reports from drug firms and FDA staff. We find significant abnormal options trading before the final reports are created and the committees meet, particularly for small drug firms. These options trades appear to be informed because there are more calls (puts) purchased before approvals (rejections), and a majority have maturities covering the dates when the reports are publicly released. Our results imply that securities regulators should consider monitoring trades early, well before FDA drug approval decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available